Do We Get Samples of the Report?

Yes, you will receive a sample copy of the market research report from the sales team when you put a query to us. The sample report is free and offers a brief view of the report and information on data available before you purchase the full-fledged report. Also, we will provide a demo sample for any oncoming study.

How to Buy a Market Report?

Select the report you wish to purchase and proceed to buy it by making an online payment. We use a secured gateway for payment transfers and do not share your financial information with any unconcerned third party.

In Which Format Will I Get the Report?

The report will be delivered in spreadsheet and PDF format. In some cases, PPT formats could be available as well.

In How Much Time I will Get the Report After Purchase?

After confirmation of the payment, you will receive the electronic format of the report at your registered email address in (mention the timeline for the delivery). If you buy a report over a holiday or weekend, we will process the request the next working day.

How Can I Get the Report Customized?

Market studies and reports already contain important data and are ready for distribution to the purchaser. However, if there is any particular query, addition, or customization you require, then contact us on our email id or phone. We will look to accommodate your request and see what can be done at the earliest. The research team will design the report accordingly and discuss the solutions beforehand with you.

How Much Will It Cost to Get a Report Customized?

The price of the customized report will be conveyed to you by our team after we agree on the deliverable. A delivery timeline will be set so that you get the report within the expected date. Any requests for customizations after selling the report will be handled by a separate department and the prices for the same mentioned upfront.

Can I Buy Only a Particular Segment of the Study?

While usually such a request is not accommodated as any market research report is wholesome and the cost of the report is for overall contents, in special cases, we may be able to sell select segments of the report based on your requirements.

Is There Any Available Discount?

Our team will love to support academicians, start-ups, students, and others with consulting and research. Thus, our pricing plan is based on keeping these interests in mind and is already affordable. However, we may have discounts available for particular customer types and reports. So, contact us for more information.

Which Services Are Complimentary Before Purchasing the Report?

We have consumer-centric reports and offer several facilities before selling. You will get a free review and sample report, talk to our customer care team for any additions to be done and meet special requirements, and interact with our analysts for deeper understanding.

Will I Receive a Bill or Invoice for the Report Purchased?

Yes, you will get an invoice for the purchase you made. The invoice will be sent to you electronically on your registered email id.

What If I am Unable to Find the Report in the Catalog?

We have a vast database of market reports and studies and there are a few which may not have been uploaded yet. If you are unable to find the one you want, then get in touch with our sales team by phone or email and we will connect with you for assistance.

How Often Are the Existing Studies Updated?

Not every study is the same. Thus, the update for reports will depend on the ongoing research and changes if any to be incorporated in the document or not.

What If the Report Does Not Contain the Information I Want?

The market research reports are constructed keeping in mind the industry trends, nature of the study, and required inputs. But if you want something more than what is stated in the report, we can help you out with further research if possible. Contact us right away, and we will do the needful to aid you.

Is the Payment Refundable?

Once the payment is done, it is non-refundable because as per the standard policy, the utility of the reports is based on knowledge sharing, and thus, a refund is not possible to make after we have issued you obtain the study. To avoid the hassle, we have a detailed view of the report and its ideas through a sample report.

What If the Payment Fails?

If the payment fails then be assured that you shall receive the money back to the source payment mode from the payment gateway. Aarkstore is not responsible for any loss of payment in the process.

Can I Avail the Report of a Particular Country/Region?

Yes, we can provide a report or segment related to a particular region or geography if we have that feature available for the document.

Do You Offer Support After Purchase?

Yes, we are here to solve any queries you may have for the report from our analyst till a given timeframe. To understand more about this, get in touch with us.

Melanocyte Stimulating Hormone Receptor - Pipeline Review, H2 2019

DESCRIPTION

TABLE OF CONTENTS

RELATED REPORTS

SAMPLE REQUEST

REVIEWS

DESCRIPTION

Melanocyte Stimulating Hormone Receptor - Pipeline Review, H2 2019

According to the recently published report Melanocyte Stimulating Hormone Receptor - Pipeline Review, H2 2019; Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) pipeline Target constitutes close to 9 molecules.

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Melanocyte-stimulating hormone receptor (MSHR) also known as melanocortin 1 receptor (MC1R), is a G protein-coupled receptor that binds to a peptide hormones known as the melanocortins, which include adrenocorticotropic hormone (ACTH). When activated by alpha-MSH, MC1R initiates a complex signaling cascade that leads to the production of the brown or black pigment eumelanin. The receptor also antagonize by agouti signaling peptide which reverts the cell back to producing the yellow or red phaeomelanin.

The report Melanocyte Stimulating Hormone Receptor - Pipeline Review, H2 2019 outlays comprehensive information on the Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 6 respectively. Report covers products from therapy areas Dermatology, Gastrointestinal, Central Nervous System, Genito Urinary System And Sex Hormones, Immunology, Metabolic Disorders, Musculoskeletal Disorders, Ophthalmology, Genetic Disorders and Oncology which include indications Diabetic Retinopathy, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Uveitis, Vitiligo, Gouty Arthritis (Gout), Infantile Spasm (West Syndrome), Keratoconjunctivitis Sicca (Dry Eye), Kidney Disease (Nephropathy), Metastatic Melanoma, Nephrotic Syndrome, Peritonitis, Porphyria (Erythropoietic Protoporphyri), Porphyria Variegata, Psoriatic Arthritis, Systemic Lupus Erythematosus and Ulcerative Colitis.

Scope
- The report provides a snapshot of the global therapeutic landscape for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
- The report reviews Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

TABLE OF CONTENTS

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Overview
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Companies Involved in Therapeutics Development
Aequus BioPharma Inc
Clinuvel Pharmaceuticals Ltd
Eton Pharmaceuticals Inc
Palatin Technologies Inc
SolaranRx Inc
SynAct Pharma AB
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Drug Profiles
afamelanotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-1189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQB-565 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CUV-9900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Parvysmelanotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-8177 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-9643 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRX-1177 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Dormant Products
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Discontinued Products
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Product Development Milestones
Featured News & Press Releases
Dec 16, 2019: First patient enrolled in Mallinckrodt phase 4 trial of Acthar Gel (Repository Corticotropin Injection) for Severe Keratitis
Nov 26, 2019: Data on Acthar Gel (Repository Corticotropin Injection) Therapy in Symptomatic Sarcoidosis published in Therapeutic Advances in Respiratory Disease
Nov 12, 2019: Mallinckrodt announces new clinical data evaluating Acthar Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis (RA) at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting
Nov 11, 2019: SynAct receives approval from the Swedish Medical Product Agency and the Swedish Ethical Review Authority regarding the clinical Phase IIa study with AP1189
Nov 07, 2019: Mallinckrodt announces data Publication on the treatment Effectiveness of Acthar Gel (Repository Corticotropin Injection) for resolution of multiple sclerosis relapse in a U.S. Health Plan Population
Oct 30, 2019: CLINUVEL: TGA Priority Registration Pathway for Scenesse
Oct 17, 2019: Palatin presents on Pl8177 oral colon delivery formulation for Ulcerative Colitis at The 7Th CPC Symposium On Peptide Therapeutics
Oct 10, 2019: Clinuvel obtains US approval for rare disorder drug Scenesse
Oct 02, 2019: FDA clarifies Scenesse PDUFA Date
Oct 01, 2019: Redeye initiates coverage of SynAct Pharma
Oct 01, 2019: Mallinckrodt announces positive top-line findings from its observational registry assessing relapse recovery in multiple sclerosis relapse patients treated with Acthar Gel (Repository Corticotropin Injection)
Sep 13, 2019: Mallinckrodt analysis suggests Acthar Gel may be a cost-effective option compared to other late-line, adult treatments for Multiple Sclerosis Relapse
Sep 10, 2019: SCENESSE presented at ICPP in Milan
Aug 06, 2019: Palatin Technologies to present data on anti-inflammatory drug PL-8177 at Canaccord Genuitys 39th Annual Growth Conference
Jul 17, 2019: Mallinckrodt ends Acthar Gels Phase IIb trial in ALS
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Aequus BioPharma Inc, H2 2019
Pipeline by Clinuvel Pharmaceuticals Ltd, H2 2019
Pipeline by Eton Pharmaceuticals Inc, H2 2019
Pipeline by Palatin Technologies Inc, H2 2019
Pipeline by SolaranRx Inc, H2 2019
Pipeline by SynAct Pharma AB, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

List Of Figures

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

RELATED REPORTS

SAMPLE REQUEST

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

REVIEWS

There is no Reviews available

Search and Get the Latest Market Research Reports

Melanocyte Stimulating Hormone Receptor - Pipeline Review, H2 2019

Melanocyte Stimulating Hormone Receptor - Pipeline Review, H2 2020

Melanocyte Protein PMEL - Pipeline Review, H2 2019

Follicle Stimulating Hormone Receptor (Follitropin Receptor or FSHR) - Drugs in Development, 2021

Thyrotropin Receptor (Thyroid Stimulating Hormone Receptor or TSHR) - Drugs in Development, 2021

FAQs